Zafgen (ZFGN) PT Lowered to $46 at RBC Capital; Discusses Road Ahead for Beloranib
Tweet Send to a Friend
RBC Capital analyst Simos Simeonidis maintained an Outperform rating and lowered his price target on Zafgen (NASDAQ: ZFGN) to $46.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
